The expression levels of immune checkpoint-related genes play a crucial role in HCC immunotherapy, and our findings indicate that YTHDF1, CD86, and CD80 were significantly overexpressed in the high-risk group (Fig. 6A). Here, CD86 is linked to hepatocellular carcinoma.